Revolution Medicines - Biotech company impresses with strong pipeline!
Reading Time: 1 minute
Business Driver: Revolution Medicines (RVMD) specializes in the development of new therapeutic approaches for the treatment of cancer and tumor cells. Central to this are the so-called RAS(ON) inhibitors and RAS co-inhibitors, which target hard-to-treat tumors. Currently, the company has three candidates in advanced stages of clinical testing: Daraxonrasib (RMC-6236), Zoldonrasib (RMC-9805), and Elironrasib (RMC-6291). Daraxonrasib is considered one of the most promising candidates in Revolution Medicines' portfolio. The FDA has already granted...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
